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In coinfected HBV/HCV patients, HBV replication is usually suppressed by HCV over the
time. No study to date has evaluated the HBV viremia in long-term follow-up after HCV
treatment in hemodialysis patients with HBV/HCV coinfection. This study aimed to assess
the  evolution of HBV viremia after HCV treatment in this special population. Ten hemodial-
ysis  patients with HBV/HCV coinfection with dominant HCV infection (HBV lower than
2000 IU/mL) and signiﬁcant ﬁbrosis were treated with interferon-alpha 3 MU 3×/week for 12
months and could be followed for at least 36 months after HCV treatment. Six cases of HBV
reactivation (60%) during follow-up were observed and 5/6 had been successfully treated for
HCV. Patients with HBV reactivation received anti-HBV therapy. Our preliminary ﬁndings
indicate that treatment of hepatitis C in HBV/HCV coinfected hemodialysis patients mayfavor HBV reactivation. Thus, continued monitoring of HBV viremia must be recommended
and prompt anti-HBV therapy should be implemented.
© 2015 Elsevier Editora Ltda. All rights reserved.epatitis C virus (HCV) coinfection occurs in 7–15% of patients
ith chronic HBV infection. It is more  frequent in intravenous
rug users, in endemic areas of HBV, and in hemodialysis
atients.1 Although chronic HBV infection in patients on dial-
sis is usually asymptomatic and indolent, HBsAg positivity
s an independent risk factor for renal graft failure after kid-
ey transplantation.2,3 Moreover, most studies show higher
∗ Corresponding author at: Rua Martiniano de Carvalho, 905, 013210-000
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413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.mortality in renal transplant recipients infected with HBV,
compared with renal transplant recipients without hepatitis
B virus (HBV) infection.
In HBV/HCV coinfected patients, HBV replication is usually São Paulo, SP, Brazil.
suppressed by HCV. Nevertheless, in many  cases, a dynamic
viral interference between HBV and HCV does exist and viral
levels of both viruses may vary during follow-up.4 In patients
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Table 1 – Demographic, clinical and laboratory characteristics of patients at baseline and during follow-up.
Total (n = 10) HBV reactivation (n = 6) No HBV reactivation (n = 4)
Age, years, mean ± SD 40 ± 10 44 ± 9 37 ± 9
Mean time of follow-up, months 40 43 38
Mean time of HBV reactivation, months, mean ± SD – 22 ± 9 –
Male gender, n/% 6/60% 4/67% 2/50%
Advanced ﬁbrosis (F ≥ 3) 2/20% 0 2/50%
Anti-HBe (+) at HCV EOT, n/% 8/80% 5/83% 3/75%
Loss of HBsAg, n/% 0 0 0
Undetectable HBV-DNA at HCV EOT, n/% 10/100% 6/100% 4/100%
SVR HCV, n/% 7/70%  5/83% 2/50%
se; EAbbreviation: SD, standard deviation; SVR, sustained virologic respon
with undetectable HBV-DNA, treatment for hepatitis C may
cause reactivation of HBV replication, as has been reported
in several patients, reaching 61.8% in the latest study with
pegylated-IFN and ribavirin in non-uremic patients.5 To the
best of our knowledge, there is no data regarding long-term
follow-up after treatment for HCV in hemodialysis patients
with HBV/HCV coinfection. Therefore, this study aimed to
assess the evolution of HBV viremia after treatment of hep-
atitis C in hemodialysis patients with HBV/HCV coinfection.
LAM + ADV
LAM
Case 1
Case 2
10
8
6
4
2
0
EOT 12 18 24 36
4
5
2
3
0
EOT 12 3024 36 48
LAM
HBV HCV
Case 3
4
5
2
3
0
EOT 12 3024 36 48
4
5
2
3
0
Fig. 1 – Proﬁles of serum HCV-RNA and HBV-DNA in six patients
treatment in months. HCV-RNA and HBV-DNA levels are express
are 50 IU/mL. Abbreviation: EOT, end of hepatitis C treatment; LAOT, end of treatment.
A retrospective analysis of HBV viremia was performed in
a cohort of patients on hemodialysis with HBV/HCV coinfec-
tion treated for hepatitis C. We  included HBV/HCV coinfected
patients with dominant HCV infection (HBV lower than
2000 IU/mL) that had been treated with interferon-alpha 3 MU
3×/week for 12 months at the Hepatitis Unit of Federal Uni-
versity of São Paulo from January 1999 to December 2010.
At the end of HCV treatment the patients with no signif-
icant HBV viremia could be followed for at least three years
LAM Case 5
4
5
2
3
0
EOT 126 24 36
LAM Case 6
EOT 12 3024 36 48
LAM Case 4
4
5
2
3
0
EOT 12 3024 36 48
 with HBV reactivation during follow-up after HCV
ed as log10 IU/mL and lower limit of detection of both tests
M, lamivudine; ADV, adefovir.
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Table 2 – Virological characteristics before HCV treatment, follow-up at month 6 and most recent follow-up.
No. Before HCV treatment Follow-up month 6 Most recent follow-up HBV treatment
HBeAg
status
HBV-DNA
(IU/mL)
HBV-GT HCV-DNA
(IU/mL)
HCV-GT HBeAg
Status
HBV-DNA
(IU/mL)
HCV-DNA
(IU/mL)
Follow-up
(months)
HBeAg
Status
HBV-DNA
(IU/mL)
HCV-DNA
(IU/mL)
1 − 1771 D + 1A − Neg. Neg. 48 − Neg. Neg. LAM
2 − Neg. − 255 1A − Neg. + 48 − Neg. + LAM
3 − 250 D + 1A − Neg. + 36 − Neg. + −
4 − Neg. A2 + − − 2061 Neg. 36 − Neg. Neg. LAM
5 − 1409 D 134 − − Neg. Neg. 40 − Neg. Neg. LAM + ADV
6 − Neg. − + − − Neg. + 44 − Neg. + −
7 − 1306 D 36,672 1A − 964 Neg. 36 − Neg. Neg. −
8 − 167 D + − − Neg. Neg. 48 − Neg. Neg. LAM
9 − Neg. − + − − Neg. Neg. 36 − Neg. Neg. −
10 − Neg. − + 1A − Neg. Neg. 36 − Neg. Neg. LAM
Abbreviation: GT, genotype; LAM, lamivudine; ADV, adefovir.
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in order to assess HBV reactivation. Patients with signiﬁcant
HBV viremia at the end of HCV treatment or with early HBV
reactivation during HCV treatment were excluded from fur-
ther follow-up.
Serum markers HBsAg, HBeAg and anti-HCV were assayed
using commercially available enzyme immunoassay kits
(Abbott Laboratories, USA).
HBV viral load were performed every three months dur-
ing follow-up. Serum HCV-RNA was determined at the end
of treatment and six months after stopping therapy to eval-
uate sustained virologic response (SVR) to HCV therapy and
determined annually thereafter.
Serum HBV-DNA was quantiﬁed by real-time PCR with a
lower detection limit of 50 IU/mL and HBV genotypes were
determined using a line probe assay (INNo-LiPA HBV Genotyp-
ing, Innogenetics NV, Belgium). Serum HCV-RNA was detected
with an HCV RNA qualitative assay (Cobas Amplicor 2.0, Roche
Diagnostics, Basel, Switzerland) with a lower detection limit of
50 IU/mL. HCV Genotyping was performed using a line probe
assay (INNo-LiPA HCV II, Innogenetics NV, Belgium).
All patients gave a written informed consent prior to liver
biopsy and/or IFN treatment. This study protocol was submit-
ted to local Ethics Committees and followed all of the ethical
premises of the Helsinki Declaration.
Herein we  report long-term follow-up data of 10 HBV/HCV
coinfected patients on hemodialysis that could be followed for
at least three years after HCV therapy. Baseline clinical and
laboratorial characteristics are shown in Table 1. During the
follow-up period, 6/10 patients showed HBV reactivation (60%)
22 ± 9 months after the end of HCV treatment and only one
case of early reactivation (within the ﬁrst six months of follow-
up) was observed (Table 2). Characteristics of HBV viremia
over time in the six cases of HBV reactivation are shown in
Fig. 1. In the only case of HBV reactivation without SVR for
HCV therapy, a dynamic viral interaction was observed dur-
ing follow-up (case #6). At ﬁrst, there was active HCV infection
and HBV-DNA was undetectable at the end on HCV treatment;
24 months later, occurred reactivation of HBV infection and
HCV-RNA became negative. After introduction of lamivudine
for HBV treatment there was a sustained suppression of HBV
viral load and reappearance of HCV-RNA.
No case of HBsAg loss was observed during the follow-up
period. In our series, all six cases with signiﬁcant elevation
of HBV viremia were treated promptly regardless of ALT ele-
vation considering that all patients had signiﬁcant ﬁbrosis
at baseline and most of them were already listed for kidney
transplantation. In ﬁve patients treatment was initiated with
lamivudine 10 mg/day since at that time entecavir or teno-
fovir were not available yet. One patient with very high viral
load used lamivudine 10 mg/day plus adefovir 10 mg/week,
to reduce the chance of virologic breakthrough. There were
no fatal cases due to HBV reactivation and the six patients
were released for renal transplantation with undetectable HBV
viremia while maintaining continued use of oral antiviral
treatment.
This is the ﬁrst report of HBV reactivation after HCV treat-
ment in coinfected HBV/HCV hemodialysis patients. Our study
showed a similar rate of HBV reactivation as recently reported
by Yu et al., in a cohort of 76 non-uremic coinfected patients,
with pretreatment undetectable HBV-DNA.5 In that study, 1 5;1  9(5):533–537
reappearance of HBV-DNA was found in 47 (61.8%) patients
that occurred either during the course of treatment (38.3%)
or during post-treatment follow-up (61.7%). Other studies in
non-uremic patients also reported a frequent rate of HBV
reactivation after HCV treatment, with rates varying from
15.4% to 100%.6–11
In our study, we  also observed that HBV reactivation
occurred more  frequently in patients who had been success-
fully treated for HCV. Two Asian studies also observed that
HBV reactivation rate was signiﬁcantly higher among those
who achieved HCV SVR (44.8 and 33.3%) compared to those
without HCV SVR (8.7 and 8.3%).7,11 According to a recent
meta-analysis by Liu et al. the risk of reappearance of HBV-
DNA in coinfected HBV/HCV patients was three times higher
in those who achieved HCV SVR (p = 0.009).12
Despite of reappearance of HBV after HCV treatment, it
has not resulted in clinically evident hepatitis. Other stud-
ies in non-uremic patients also observed the same ﬁnding
and spontaneous resolution of HBV viremia seems to be
frequent.13,14 In the Asian cohort of 76 patients, this phe-
nomenon was transient in 44.7%, intermittent in 25.5% and
sustained in 29.8%.5 The impact of the HBV reactivation in the
setting of end-stage renal disease may have an unfavorable
outcome, considering that these patients have an impaired
immume  system, affecting both acquired as well as innate
immunity.15,16 Thus, reactivation of HBV in this population
may lead to greater chance of developing chronic liver dis-
ease before renal transplant, and hepatic decompensation
after renal transplantation with the use of immunosuppress-
ive therapy.17
Due to the scarcity of data so far, the signiﬁcance of HBV
reappearance after effective treatment of HCV in patients
with chronic HBV/HCV coinfection in uremic patients requires
further analysis. Up to now, treatment with oral nucleo-
sides/nucleotides in patients under hemodialysis should be
started in cases of HBV-DNA >2000 IU/mL, regardless of ALT
activity especially if they have signiﬁcant ﬁbrosis on liver
biopsy or estimated by a non-invasive marker.18
In conclusion, our data showed that in HBV/HCV coinfected
hemodialysis patients reactivation of HBV infection is a fre-
quent phenomenon after treatment of hepatitis C. Continued
monitoring of HBV viremia must be recommended for these
patients in order to establish early antiviral treatment, espe-
cially in patients who are candidates for renal transplantation.
Based on this evidence, transplant physicians should be aware
of the risk of HBV reactivation in coinfected patients especially
when HCV has been eradicated before renal transplantation.
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